SCHEMBL6718388

SCHEMBL6718388

Cc1onc(-c2ccc(F)cc2)c1-c1ccc(S(N)(=O)=O)c(F)c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 14/20 0.69
▸ PTGS1 P23219 5/20 0.60
▸ MT-CO2 P00403 3/20 0.53
▸ CA12 O43570 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ CA3 P07451 1/20 0.53
▸ ADRB2 P07550 1/20 0.53
▸ ADRB1 P08588 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ ADORA3 P0DMS8 1/20 0.53
▸ CHRM1 P11229 1/20 0.53
▸ ADRA2B P18089 1/20 0.53
▸ CA4 P22748 1/20 0.53
▸ CA6 P23280 1/20 0.53
▸ SLC6A2 P23975 1/20 0.53
▸ PDE4A P27815 1/20 0.53
▸ ADORA1 P30542 1/20 0.53
▸ CA5A P35218 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723111 0.93 PTGS2 (0.58) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6723858 0.91 PTGS2 (0.57) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6516343 0.91 PTGS2 (0.57) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL14340248 0.91 PTGS2 (0.65) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL4805717 0.91 PTGS2 (0.65) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL31213515 0.91 PTGS2 (0.65) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6718247 0.90 PTGS2 (0.56) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6721410 0.90 PTGS2 (0.55) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6722170 0.89 PTGS2 (0.54) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6722633 0.89 BRD4 (0.56) PTGS2PTGS1MT-CO2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 — — US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 — — EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 — — US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885PTGS1 4/4885MT-CO2 3544/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885PTGS1 4/4885MT-CO2 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback